Curated News
By: NewsRamp Editorial Staff
July 14, 2026

Silo Pharma's QwikAgents Joins AMD AI Developer Program

Discuss on LinkedIn Discuss on X, formerly Twitter Discuss on Substack Discuss on Telegram participate in discussion on bluesky Participate in discussion on Mastodon View History of this news story on GitHub
Original Source

TLDR

  • Silo Pharma gains competitive edge by joining AMD AI Developer Program, accelerating its AI agent platform for enterprise and consumer markets.
  • QwikAgents, a Silo Pharma subsidiary, uses AMD Developer Cloud credits and tools to optimize deployment of persistent AI agents for automation tasks.
  • Silo Pharma's AI platform aims to simplify daily tasks through automation, freeing people to focus on more meaningful work.
  • Silo Pharma's subsidiary QwikAgents is building AI agents that can research, code, and schedule tasks autonomously.

Impact - Why it Matters

This news matters because it signals Silo Pharma's strategic expansion into artificial intelligence, diversifying beyond its core biopharmaceutical focus. By joining the AMD AI Developer Program, QwikAgents gains access to cutting-edge tools and resources that could significantly accelerate the development of its AI agent platform. For investors, this move may open new growth avenues and potentially enhance the company's valuation. For the tech community, it represents another example of AI integration in business operations, showcasing how even biopharma companies are leveraging AI to create value.

Summary

Silo Pharma (NASDAQ: SILO) is making waves in the AI space through its wholly owned subsidiary, QwikAgents, which has been accepted into Advanced Micro Devices’ AMD AI Developer Program. This strategic move grants QwikAgents access to AMD Developer Cloud credits, AI development tools, training resources, and a global developer community. The company aims to leverage these resources to accelerate the development, testing, optimization, and deployment of its AI agent platform across consumer and enterprise applications. QwikAgents is building a platform that allows users to deploy persistent AI agents for tasks such as research, content generation, scheduling, coding, and workflow automation. By joining the AMD program, Silo expects to enhance platform performance, agent reliability, and scalable deployment as it expands its capabilities for individuals, developers, small businesses, and enterprise customers.

Beyond its AI initiatives, Silo Pharma is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company. Its therapeutic focus includes stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The company’s pipeline features innovative programs like SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer’s disease and multiple sclerosis. Silo conducts research in collaboration with leading universities and laboratories. The news was disseminated by InvestorWire, a specialized communications platform that offers wire-grade press release syndication and enhanced distribution services to private and public companies.

For investors, the latest news and updates relating to SILO are available in the company’s newsroom at https://ibn.fm/SILO. The full press release can be accessed at https://ibn.fm/313SC. Silo’s participation in the AMD AI Developer Program marks a significant step in bridging AI technology with its broader business strategy, potentially opening new revenue streams and operational efficiencies.

Source Statement

This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Silo Pharma's QwikAgents Joins AMD AI Developer Program

blockchain registration record for this content.